Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar;31(3):194-207.
doi: 10.1111/iju.15362. Epub 2023 Dec 19.

Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association

Kazuyuki Mori  1 , Shingo Hatakeyama  1 , Hideki Enokida  2 , Hideaki Miyake  3 , Eiji Kikuchi  4 , Hiroyuki Nishiyama  5 , Tomohiko Ichikawa  6 , Takao Kamai  7 , Yasushi Kaji  8 , Haruki Kume  9 , Tsunenori Kondo  10 , Hideyasu Matsuyama  11 , Naoya Masumori  12 , Akihiro Kawauchi  13 , Atsushi Takenaka  14 , Hirotsugu Uemura  15 , Masatoshi Eto  16 , Norio Nonomura  17 , Yasuhisa Fujii  18 , Shiro Hinotsu  19 , Chikara Ohyama  1
Affiliations
Review

Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association

Kazuyuki Mori et al. Int J Urol. 2024 Mar.

Abstract

This article is an English translation of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma (2nd edition) published in June 2023. The Japanese Urological Association's (JUA) Guidelines Committee on Upper Tract Urothelial Carcinoma (UTUC) created a 2023 update guideline to support clinicians' current evidence-based management of UTUC and to incorporate its recommendations into clinical practice. The new guideline adhered as closely as possible to the Minds Manual for Guideline Development 2020 ver. 3.0. Findings related to epidemiological, pathological, diagnosis, treatment, and follow-up were reviewed. In addition, seven clinical questions (CQs) were set to determine the grade of recommendation and level of evidence. Preconceptions and biases were removed from the preparation process, the overall evidence was evaluated appropriately, and recommendations were made after fully considering the balance between benefits and harms. Although the evidence is still insufficient to be taken up as a CQ, the latest important information is described in seven columns, and clinical issues that should be resolved in the future related to the CQ are described as recommendations for tomorrow. We hope that these guidelines will help medical professionals, patients, and their families involved in the treatment of UTUC in their decision-making, and hope that a critical review of these guidelines will lead to further refinements in the next edition.

Keywords: clinical practice guideline; diagnosis; evidence-based medicine; treatment; upper tract urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

This guideline was formulated for the purpose of contributing to society, and its content is strictly based on scientific grounds. COI declarations by all members involved in the development of these guidelines have been carefully scrutinized by COI Committee of JUA and have concluded that there is no material COI‐related interference. COI for each member was managed by JUA and published on the JUA website. In order to eliminate competing interests with specific organizations, products, and technologies, we have taken steps such as banning certain potential COI members from voting on CQ.

Figures

FIGURE 1
FIGURE 1
Clinical algorithm for diagnosis of UTUC.
FIGURE 2
FIGURE 2
Diagnosis and treatment algorithm for surgical treatment of UTUC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. The Japanese Urological Association, the Japanese Society of Pathology, Japan Radiological Society, and Japanese Society of Medical Oncology , editor. General rule for clinical and pathological studies on renal pelvic, ureteral and bladder cancer. 2nd ed. Tokyo: Igaku Tosho Shuppan; 2021.
    1. Minds Manual Developing Committee , editor. Minds manual for guideline development 2020 ver. 3.0. Tokyo: Japan Council for Quality Health Care; 2021.
    1. Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79:62–79. - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33. - PubMed
    1. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol. 2017;24:730–734. - PubMed

MeSH terms